 |
|
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online 2022 Nov 29 DOI: https://doi.org/10.3350/cmh.2022.0367
|
|
Citations to this article as recorded by
 Pre-MASLD: Should it be defined separately?
Hang-Kai Huang, You-Ming Li, Cheng-Fu Xu
Hepatobiliary & Pancreatic Diseases International.2024; 23(1): 1. CrossRef Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning
Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu, Ming‐Hua Zheng
Liver International.2024; 44(2): 330. CrossRef Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
Diabetes & Metabolism.2024; 50(1): 101506. CrossRef Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice
Jinuk Seo, Doyoung Kwon, Sou Hyun Kim, Mi Ran Byun, Yun-Hee Lee, Young-Suk Jung
Current Research in Food Science.2024; 8: 100663. CrossRef Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus
Ziqiao Yuan, Hui Qiao, Ziwei Wang, Haoran Wang, Mingru Han, Wenzhou Zhang, Yang Zhou, Hozeifa Mohamed Hassan, Wen Zhao, Tingting Qin
Phytomedicine.2024; 126: 155315. CrossRef Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice
Hassam Ali, Muhammad Shahzil, Vishali Moond, Maria Shahzad, Abhay Thandavaram, Alina Sehar, Haniya Waseem, Taha Siddiqui, Dushyant Singh Dahiya, Pratik Patel, Hans Tillmann
Journal of Personalized Medicine.2024; 14(1): 61. CrossRef Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini
Metabolites.2024; 14(1): 52. CrossRef Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial
Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Juan J Martin-Olmedo, Francisco Amaro-Gahete, Rocío Cupeiro, María Trinidad González Cejudo, Patricia Virginia García Pérez, Carlos Hernández-Martínez, Raquel Sevilla-Lorente, Alejandro De-la-O, Alejandro Ló
BMJ Open.2024; 14(1): e078472. CrossRef Association of sex-specific body mass index and waist circumference trajectories with non-alcoholic fatty liver disease incidence based on growth mixture modeling
Tengrui Cao, Chao Tong, Qiang Li, Yumei Han, Aheyeerke Halengbieke, Xuetong Ni, Bo Gao, Deqiang Zheng, Xinghua Yang
Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(5): 1245. CrossRef Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components
Dongsheng Ran, ChunLing Xin, Yingcai Ma, Yanyan Lu
Clinics and Research in Hepatology and Gastroenterology.2024; 48(3): 102302. CrossRef A Cross-Sectional Investigation for Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Tibetan College Students in Mainland
娟 周
Advances in Clinical Medicine.2024; 14(02): 2843. CrossRef The Global Epidemic of Metabolic Fatty Liver Disease
Ethan C. Z. Lee, Vickram V. Anand, Alex C. Razavi, Pamela L. Alebna, Mark D. Muthiah, Mohammad S. Siddiqui, Nicholas W. S. Chew, Anurag Mehta
Current Cardiology Reports.2024; 26(4): 199. CrossRef Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)
Jiaqin Gao, Bin Zuo, Yang He
Molecular Medicine Reports.2024;[Epub] CrossRef Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Evgenia Koureta, Evangelos Cholongitas
Frontiers in Pharmacology.2024;[Epub] CrossRef Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease
Shuang Wang, Qiang Zhang, Bo Qin
Scientific Reports.2024;[Epub] CrossRef Identification of crosstalk genes relating to ECM‐receptor interaction genes in MASH and DN using bioinformatics and machine learning
Chao Chen, Yuxi He, Ying Ni, Zhanming Tang, Wensheng Zhang
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob Georg
Liver International.2024; 44(5): 1129. CrossRef Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin
Heliyon.2024; 10(5): e27325. CrossRef Association of multiple serum minerals and vitamins with metabolic dysfunction-associated fatty liver disease in US adults: National Health and Nutrition Examination Survey 2017–2018
Peisen Guo, Jiahui Yu
Frontiers in Nutrition.2024;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo
Frontiers in Nutrition.2024;[Epub] CrossRef Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
Yu Kong, Zhongcai Yao, Lingli Ren, Liqin Zhou, Jinkai Zhao, Yuanyuan Qian, Dayong Lou
Frontiers in Psychiatry.2024;[Epub] CrossRef A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD
Zhonglin Li, Rui Gong, Huikuan Chu, Junchao Zeng, Can Chen, Sanping Xu, Lilin Hu, Wenkang Gao, Li Zhang, Hang Yuan, Zilu Cheng, Cheng Wang, Meng Du, Qingjing Zhu, Li Zhang, Lin Rong, Xiaoqing Hu, Ling Yang
Atherosclerosis.2024; 392: 117526. CrossRef Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats
Rubén Tovar, Marialuisa de Ceglia, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Anna Boronat, Rafael de la Torre, Fernando Rodríguez de Fonseca, Elena Baixeras, Juan Decara
ACS Pharmacology & Translational Science.2024; 7(5): 1571. CrossRef Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study
Lin Tuo, Li-ting Yan, Yi Liu, Xing-xiang Yang
Frontiers in Endocrinology.2024;[Epub] CrossRef Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites.2024; 14(4): 218. CrossRef Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review
Kasey Moss, Victor Gitman, M Ines Pinto Sanchez, Simon Oczkowski, David Armstrong, Saumya Jayakumar, Constantine Jason Karvellas, Nazia Selzner, Joanna Dionne
BMJ Open.2024; 14(4): e079750. CrossRef Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Liver Cancer.2024; : 1. CrossRef Prevalence of Nonalcoholic Fatty Liver Disease [NAFLD] and Metabolic dysfunction associated Fatty Liver Disease [MAFLD] in patients with Irritable Bowel Syndrome [IBS]
Md. Musab Khalil, Sirajam Munira, Md. Mahbubul Alam, Al Mahmood Appolo, Musatafa Md. Abu Sayeed, Atikul Islam, Narwana Khaleque, Mohammad Faisal, Arifa Tasnim, Ruma Najnin, Mahmudur Rahman, Enamul Karim, Md. Golam Kibria
SN Comprehensive Clinical Medicine.2024;[Epub] CrossRef Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study
Xiaoyuan Zhong, Dawei Huang, Rongfen Chen, Lingling Yao, Rui Ma, Yingyuan Yu, Yuxiong Jiang, Luyang Kong, Jiajing Lu, Ying Li, Yuling Shi
Frontiers in Immunology.2024;[Epub] CrossRef Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung
Scientific Reports.2024;[Epub] CrossRef Essential Oils for the Treatment and Management of Nonalcoholic Fatty Liver Disease (NAFLD)
Taehwa Kim, Mohammad Al Mijan, Jeonga Lee, Jungmi Yun, Jae Heun Chung, Soo Min Son, Ryuk Jun Kwon
Natural Product Communications.2024;[Epub] CrossRef Curcuma wenyujin rhizomes extract ameliorates lipid accumulation
Hong Wang, Lijia Chen, Ruiyu Zhang, Guanying Zhang, Jingwen Liu, Fujiang Guo
Fitoterapia.2024; 175: 105957. CrossRef The Role of PNPLA3_rs738409 Gene Variant, Lifestyle Factors, and Bioactive Compounds in Nonalcoholic Fatty Liver Disease: A Population-Based and Molecular Approach towards Healthy Nutrition
Meiling Liu, Sunmin Park
Nutrients.2024; 16(8): 1239. CrossRef Prevalence of metabolic dysfunction-associated fatty liver disease and its association with glycemic control in persons with type 2 diabetes in Africa: A systematic review and meta-analysis
Emmanuel Ekpor, Samuel Akyirem, Precious Adade Duodu, Bert B. Little
PLOS Global Public Health.2024; 4(5): e0002835. CrossRef Role of FXR in the development of NAFLD and intervention strategies of small molecules
Jiachan Long, Yuanhang Xu, Xuerong Zhang, Bingxing Wu, Caiyan Wang
Archives of Biochemistry and Biophysics.2024; 757: 110024. CrossRef Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum
Josep León-Mengíbar, Enric Sánchez, Ferrán Herrerías, Mari Cruz De La Fuente, Maite Santamaría, José Manuel Valdivielso, Marcelino Bermúdez-López, Eva Castro, Judit Pallarés, Xavier Matias-Guiu, Felip Vilardell, Assumpta Caixàs, Marta Bueno, Raquel Martí,
Frontiers in Endocrinology.2024;[Epub] CrossRef Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective
Shelley E. Keating, Yogesh Chawla, Arka De, Elena S. George
Hepatology International.2024;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions
O.E. Abaturov, A.O. Nikulina
CHILD`S HEALTH.2024; 19(2): 107. CrossRef Early life exposure to vitamin D deficiency impairs molecular mechanisms that regulate liver cholesterol biosynthesis, energy metabolism, inflammation, and detoxification
Megan M. Knuth, Jing Xue, Marwa Elnagheeb, Raad Z. Gharaibeh, Sarah A. Schoenrock, Susan McRitchie, Cory Brouwer, Susan J. Sumner, Lisa Tarantino, William Valdar, R. Scott Rector, Jeremy M. Simon, Folami Ideraabdullah
Frontiers in Endocrinology.2024;[Epub] CrossRef Deconvolution analysis identified altered hepatic cell landscape in primary sclerosing cholangitis and primary biliary cholangitis
Hoang Nam Pham, Linh Pham, Keisaku Sato
Frontiers in Medicine.2024;[Epub] CrossRef Letter to the editor: Comment on “The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – A four-arm randomized controlled trial”
Luping Quan, Chao Ding, Yumeng Jin, Yaping Li
Clinical Nutrition.2024; 43(6): 1595. CrossRef Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison
Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao
Frontiers in Medicine.2024;[Epub] CrossRef Age at menopause and risk of metabolic dysfunction-associated fatty liver disease: A 14-year cohort study
Ehn-Young Kim, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee
Digestive and Liver Disease.2024;[Epub] CrossRef MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: A cross‐sectional population study
Manuela Abbate, Aneliya Parvanova, Ángel Arturo López‐González, Aina M. Yañez, Miquel Bennasar‐Veny, José Ignacio Ramírez‐Manent, Elia Reseghetti, Piero Ruggenenti
Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018
Yuxiao Zhang, Min Zhang, Shanjiamei Jiang, Heng Hu, Xinzhi Wang, Fan Yu, Yue’e Huang, Yali Liang
Cancer Causes & Control.2024;[Epub] CrossRef Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
Pegah Golabi, Soroor Owrangi, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef Azorella compacta Organic Extracts Exacerbate Metabolic Dysfunction-Associated Fatty Liver Disease in Mice Fed a High-Fat Diet
Jessica Zúñiga-Hernandez, Matías Quiñones San Martin, Benjamín Figueroa, Ulises Novoa, Francisco A. Monsalve, Mitchell Bacho, Aurelio San-Martin, Daniel R. González
Pharmaceuticals.2024; 17(6): 746. CrossRef Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β
Joey A. Muns, Erik Schooten, Rychon D. J. van Dasselaar, Yvet E. Noordman, Kevin Adamzek, Arthur C. Eibergen, Sebas D. Pronk, Sagel Cali, Niels J. Sijbrandi, Eugen Merkul, Sabrina Oliveira, Paul M.P. van Bergen en Henegouwen, R. Bart Takkenberg, Joanne Ve
European Journal of Nuclear Medicine and Molecular Imaging.2024;[Epub] CrossRef Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
Jin Imai, Shinji Takashimizu, Nana Suzuki, Kana Ohshinden, Kana Sawamoto, Yusuke Mishima, Kota Tsuruya, Yoshitaka Arase, Mitsuhiko Yamano, Noriaki Kishimoto, Chizumi Yamada, Nagamu Inoue, Kengo Moriyama, Akiyasu Baba, Hidekazu Suzuki, Tatehiro Kagawa, Yas
Scientific Reports.2024;[Epub] CrossRef Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine
Giancarlo Suffredini, Wei Dong Gao, Jeffrey M. Dodd-o
Journal of Clinical Medicine.2024; 13(13): 3633. CrossRef Importance of the gut microbiota in the gut-liver axis in normal and liver disease
Stanislav Kotlyarov
World Journal of Hepatology.2024; 16(6): 878. CrossRef Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea
Yu-Jin Kwon, Ja-Eun Choi, Kyung-Won Hong, Ji-Won Lee
Journal of Translational Medicine.2024;[Epub] CrossRef MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic
Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef Breaking Barriers: Enhancing Statins Utilization for Cardiovascular Protection in MAFLD
Faraz Arshad
The American Journal of Medicine.2024; 137(7): e142. CrossRef Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma
Xuan Zha, Zewei Gao, Min Li, Xueli Xia, Zhenwei Mao, Shengjun Wang
Biomedicine & Pharmacotherapy.2024; 177: 116966. CrossRef Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker!
Amedeo Lonardo
World Journal of Gastroenterology.2024; 30(24): 3016. CrossRef Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Associati
Magdalena Olszanecka-Glinianowicz, Artur Mazur, Jerzy Chudek, Beata Kos-Kudła, Leszek Markuszewski, Dominika Dudek, Piotr Major, Piotr Małczak, Wiesław Tarnowski, Paweł Jaworski, Elżbieta Tomiak
Nutrients.2023; 15(7): 1641. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski
International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef Metabolic dysfunction: The silenced connection with fatty liver disease
Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez
Annals of Hepatology.2023; 28(6): 101138. CrossRef MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
Journal of Gastroenterology.2023; 58(10): 947. CrossRef Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Chuan Lu, Yan Chen, Yue Zhang, Xin Zhao
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2627. CrossRef Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
Rachmad Anres Dongoran, Fang-Cen Tu, Chin-Hung Liu
Tzu Chi Medical Journal.2023; 35(4): 290. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki E. Georgakopoulou, Ioanna E. Stergiou, Stamatios Theocharis, Georgios Germanidis
International Journal of Molecular Sciences.2023; 24(19): 14704. CrossRef Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus
Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Ro
Diabetes & Metabolism.2023; 49(6): 101477. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef Vascular calcification: from the perspective of crosstalk
Shiqi Yang, Zhaolin Zeng, Qing Yuan, Qian Chen, Zuo Wang, Hui Xie, Jianghua Liu
Molecular Biomedicine.2023;[Epub] CrossRef What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez
Current Hepatology Reports.2023; 22(4): 221. CrossRef Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Divyavani Gowda, Chandra Shekhar, Siddabasave Gowda B. Gowda, Yifan Chen, Shu-Ping Hui
Livers.2023; 3(4): 687. CrossRef Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver
Decheng Meng, Fengxia Zhang, Wenfei Yu, Xin Zhang, Guoliang Yin, Pengpeng Liang, Yanan Feng, Suwen Chen, Hongshuai Liu
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4043. CrossRef Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries
Giuseppina Palladini, Laura Giuseppina Di Pasqua, Anna Cleta Croce, Andrea Ferrigno, Mariapia Vairetti
International Journal of Molecular Sciences.2023; 24(24): 17407. CrossRef Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study
Hang Zhang, Li Li, Lei Jia, Jinchun Liu
Medicine.2023; 102(51): e36658. CrossRef
|